BRPI0408979A - uso de um antagonista e receptor de tipo 1 da angiotensina ii sozinho ou em combinação com uma substáncia anti-hipertensiva metabolicamente neutra, e, método para o tratamento e/ou prevenção de sìndrome metabólica - Google Patents

uso de um antagonista e receptor de tipo 1 da angiotensina ii sozinho ou em combinação com uma substáncia anti-hipertensiva metabolicamente neutra, e, método para o tratamento e/ou prevenção de sìndrome metabólica

Info

Publication number
BRPI0408979A
BRPI0408979A BRPI0408979-0A BRPI0408979A BRPI0408979A BR PI0408979 A BRPI0408979 A BR PI0408979A BR PI0408979 A BRPI0408979 A BR PI0408979A BR PI0408979 A BRPI0408979 A BR PI0408979A
Authority
BR
Brazil
Prior art keywords
angiotensin
type
prevention
treatment
combination
Prior art date
Application number
BRPI0408979-0A
Other languages
English (en)
Inventor
Anders Ljunggren
Anders Svensson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0408979A publication Critical patent/BRPI0408979A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"USO DE UM ANTAGONISTA DE RECEPTOR DE TIPO 1 DA ANGIOTENSINA II SOZINHO OU EM COMBINAçãO COM UMA SUBSTáNCIA ANTI-HIPERTENSIVA METABOLICAMENTE NEUTRA, E, MéTODO PARA O TRATAMENTO E/OU PREVENçãO DE SìNDROME METABóLICA". A invenção refere-se ao uso de um antagonista de receptor de tipo 1 da angiotensina II sozinhos ou em combinação com uma substância anti-hipertensiva metabolicamente neutra, para a prevenção e/ou tratamento da síndrome metabólica. Exemplos de antagonista de receptor de tipo 1 da angiotensina II são os compostos da fórmula (I) e exemplos de substância anti-hipertensiva metabolicamente neutra são antagonistas de cálcio.
BRPI0408979-0A 2003-04-03 2004-03-31 uso de um antagonista e receptor de tipo 1 da angiotensina ii sozinho ou em combinação com uma substáncia anti-hipertensiva metabolicamente neutra, e, método para o tratamento e/ou prevenção de sìndrome metabólica BRPI0408979A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0300988A SE0300988D0 (sv) 2003-04-03 2003-04-03 New use
PCT/SE2004/000505 WO2004087136A1 (en) 2003-04-03 2004-03-31 Use of atii antagonist for the treatment or prevention of metabolic syndrome

Publications (1)

Publication Number Publication Date
BRPI0408979A true BRPI0408979A (pt) 2006-04-04

Family

ID=20290927

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408979-0A BRPI0408979A (pt) 2003-04-03 2004-03-31 uso de um antagonista e receptor de tipo 1 da angiotensina ii sozinho ou em combinação com uma substáncia anti-hipertensiva metabolicamente neutra, e, método para o tratamento e/ou prevenção de sìndrome metabólica

Country Status (15)

Country Link
US (1) US20060194856A1 (pt)
EP (1) EP1613309A1 (pt)
JP (1) JP2006522115A (pt)
KR (1) KR20050114671A (pt)
CN (1) CN1771033A (pt)
AU (1) AU2004226517B2 (pt)
BR (1) BRPI0408979A (pt)
CA (1) CA2520960A1 (pt)
IL (1) IL170706A0 (pt)
MX (1) MXPA05010660A (pt)
NO (1) NO20054370L (pt)
NZ (1) NZ542640A (pt)
SE (1) SE0300988D0 (pt)
WO (1) WO2004087136A1 (pt)
ZA (1) ZA200507945B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080132555A1 (en) * 2006-11-28 2008-06-05 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted phenyltetrazoles
EP2825165A1 (en) * 2012-03-16 2015-01-21 Glucox Biotech AB Thiophene-based compounds exhibiting nox4 inhibitory activity and use thereof in therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5266583A (en) * 1992-09-01 1993-11-30 Merck & Co., Inc. Angitotensin II antagonist
GB9406573D0 (en) * 1994-03-31 1994-05-25 Merck Sharp & Dohme Medicaments
DE4439947A1 (de) * 1994-11-09 1996-05-15 Boehringer Mannheim Gmbh 2,2-Dichloralkancarbonsäuren, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
ES2289814T3 (es) * 1998-07-10 2008-02-01 Novartis Pharma Ag Combinacion antihipertensiva de valsartan y bloqueador de canales del calcio.
KR20020089437A (ko) * 2000-04-12 2002-11-29 노파르티스 아게 유기 화합물의 배합
CA2420055C (en) * 2000-08-25 2010-06-01 Takeda Chemical Industries, Ltd. Fibrinogen-lowering agent
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US20030092736A1 (en) * 2001-05-30 2003-05-15 Cheng Peter T. Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
ATE551056T1 (de) * 2002-12-27 2012-04-15 Takeda Pharmaceutical Mittel zur hemmung der körpergewichtszunahme

Also Published As

Publication number Publication date
KR20050114671A (ko) 2005-12-06
NO20054370L (no) 2005-10-31
US20060194856A1 (en) 2006-08-31
AU2004226517B2 (en) 2008-01-24
NO20054370D0 (no) 2005-09-21
AU2004226517A1 (en) 2004-10-14
IL170706A0 (en) 2009-02-11
MXPA05010660A (es) 2005-12-12
WO2004087136A1 (en) 2004-10-14
SE0300988D0 (sv) 2003-04-03
JP2006522115A (ja) 2006-09-28
CA2520960A1 (en) 2004-10-14
ZA200507945B (en) 2007-04-25
NZ542640A (en) 2008-06-30
EP1613309A1 (en) 2006-01-11
CN1771033A (zh) 2006-05-10

Similar Documents

Publication Publication Date Title
WO2004100875A3 (en) Benzimidazoles, compositions containing such compounds and methods of use
WO2004069158A3 (en) Substituted pyrazoles, compositions containing such compounds and methods of use
IL140622A0 (en) Biphenyl sufonamide derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
WO2006014618A3 (en) Substituted pyrazoles, compositions containing such compounds and methods of use
UA96308C2 (ru) Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение
WO2006044362A3 (en) N-sulfonylpiperidine cannabinoid receptor 1 antagonists
WO2001044239A3 (en) Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
EA200601552A1 (ru) Замещенные конденсированные гетероциклические с-гликозиды
WO2007136577A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
NO20092470L (no) Substituerte diazepanforbindelser som orexinreseptorantagonister
TR200201057T2 (tr) P38 protein kinazı inhibitörleri olarak heteroalkilamino ikameli bisiklik nitrojen heterosaykılları.
DE60335891D1 (de) Sulphonylaminoessigsaeure derivate und deren verwendung als orexin rezeptor antagoniste
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
UA84318C2 (ru) Гетерополициклические соединения и их применение как метаботропических антагонистов рецепторов глутамата, фармацевтическая композиция на их основе
WO2006104826A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2004092135A3 (en) Substituted benzosulphonamide as potentiators of glutamate receptors
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
DK1551803T3 (da) Azabicycloderivater som muskarine receptorantagonister
ATE357917T1 (de) Behandlung von dyskinesie durch mu-selektive opioidantagonisten
WO2005060959A8 (en) Pyrazole derivatives and use thereof as orexin receptor antagonists
WO2007016087A3 (en) Heterocyclic benzodiazepine cgrp receptor antagonists
EP1549655A4 (en) SUBSTITUTED BICYCLIC THIOPHENE DERIVATIVES, COMPOSITIONS AND METHOD OF ADMINISTRATION CONTAINING SUCH COMPOUNDS
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
NO20002408L (no) 5-HT1F antagonister
DE60139770D1 (de) Hydantoin derivate mit affinität für somatostatin rezeptoren

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/41; A61P 9/12

Ipc: A61K 31/41 (2011.01), A61P 9/12 (2011.01)

B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A E 10A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A E 16A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.